Aspheric IOLs no. 1 choice for glaucoma patients

Article

An aspheric IOL may be considered the implant design of choice for most patients with glaucoma who require cataract surgery, said Richard L. Lindstrom, MD.

An aspheric IOL may be considered the implant design of choice for most patients with glaucoma who require cataract surgery, said Richard L. Lindstrom, MD.

"Providing the best quality vision is paramount in the visually compromised glaucoma patient," said Dr Lindstrom, founder and attending surgeon, Minnesota Eye Consultants, Minneapolis, US. "These individuals are known to have reduced contrast sensitivity that is related to a reduction in retinal ganglion cells.

"Given this neuronal influence, it is rational to do whatever we can to maximize contrast sensitivity on the basis of optics, and that is accomplished best with the use of an aspheric IOL," he added.

Dr Lindstrom noted there is good evidence that aspheric IOLs enhance contrast sensitivity by reducing total spherical aberration in the eye. The only situation where a spherical IOL would be preferred over an aspheric implant would be in the rare instance of a patient with glaucoma who has negative corneal spherical aberration related to previous LASIK for hyperopia.

In general, presbyopia-correcting IOLs - and particularly, current-generation multifocal designs - should be avoided in patients with glaucoma because of a potential to compromise contrast sensitivity. Laboratory measurements of modulation transfer function, however, show that an investigational, next-generation design of a proprietary accommodating IOL (crystalens HD-100; eyeonics/Bausch & Lomb) outperformed a previous model of the accommodating IOL, as well as multifocal presbyopia-correcting implants.

"For now, multifocality might be considered only if visual loss [from glaucoma] is mild and expected to stay that way," Dr Lindstrom said. "When available, the new accommodating IOL may become a reasonable compromise for select glaucoma patients who want to reduce their dependence upon glasses."

 

Read

ASCRS 2008 meeting highlights.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.